Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Updated Outlook

<< Previous

Bullboard Posts

Next >>

Comment by EbbFlow88on Aug 10, 2023 3:18pm

102 Views

Post# 35582391

RE:RE:Updated Outlook

RE: Gilead

They transfered inventory worth $6M which raised A/R, which led to increase in working capital outflows. Cash from operations would have been positive ~$4.5M for the Q excluding that transfer. They will get the money paid to them in Q3.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023